DG treatment (10 mg/kg/day, i.p. for 14 days) attenuated learning and memory impairment in Aβ_1–42-induced AD mice.

<p>(A) Escape latency for escape to a submerged platform in the training trials. (B) Searching distance for escape to a submerged platform in the training trials. * <i>P</i><0.05 and ** <i>P</i><0.01 for two-way ANOVA with repeated measures followed by Bonferroni <i>post hoc</i> test compared with Aβ_1–42-treated, respectively. (C) 24 h after the training trials platform crossing times were recorded. * <i>P</i><0.05 for one-way ANOVA followed by Tukey <i>post hoc</i> test compared with control; # <i>P</i><0.05 for one-way ANOVA followed by Tukey <i>post hoc</i> test compared with Aβ_1–42-treated. (D) Swimming speed in the training trials. con: normal mice; DG: normal mice with DG (10 mg/kg/day, i.p. for 14 days); Aβ: Aβ_1–42-induced AD mice; Aβ+DG: Aβ_1–42-induced AD mice with DG (10 mg/kg/day, i.p. for 14 days). n = 10 mice per group.